Home  Contact Us
  Follow Us On:
 
Search:
Advertising Advertising Free Newsletter Free E-Newsletter
NEWS

CanSino new vaccine plant opens in Tianjin to boost annual capacit
Published on: 2021-04-28
Share to
User Rating: / 0
PoorBest 

CanSino Biologics is expected to increase the annual production capacity of its recombinant adenovirus vector COVID-19 vaccine - the only single-dose vaccine approved in China - to 200 to 300 million doses after its third plant comes into full operation in Tianjin.
 

The 15,000-square-meter production base is in line with the international standards of Good Manufacture Practice of Medical Products (GMP), and there is an automatic line for pre-filling syringes and vials.
 

The production line adopts the adenovirus vector technology platform with independent intellectual property rights, which has been applied in the production of China's only approved Ebola vaccine developed by CanSinoBIO in 2017.
 

Vaccines produced at the plant are used in mass inoculation being rolled out in Tianjin and the surrounding region.
 

The vaccine, named Ad5-nCoV, was granted approval for emergency use in countries like Mexico, Pakistan, and Hungary.
 

It is also effective for the elderly, based on Phase-II and Phase-III trials which involved aged participants and saw no serious adverse reactions.
 

The Ad5-nCoV vaccine is jointly developed by CanSinoBIO and researchers from the Institute of Military Medicine under the Academy of Military Sciences led by prestigious vaccine expert Chen Wei.
 

The vaccine can be stored and transported at temperatures of between 2 and 8 C, and production does not require level-three biosafety laboratories, which is the case with inactivated vaccines. Experts said this makes it more accessible for developing countries with limited facilities.
 

康希诺生物新冠疫苗三期生产基地产品在天津下线

4月25日,康希诺生物股份公司位于天津经开区西区的康希诺生物新冠疫苗三期生产基地产品下线。基地新冠疫苗产品为国内目前获批上市唯一采用单针免疫的重组新型冠状病毒疫苗(5型腺病毒载体)克威莎TM,将为应对新发、突发重大传染病疫情防控提供强有力的保障。
 

位于天津经开区西区的康希诺生物新冠疫苗三期生产基地占地约15000平方米,设计符合我国和国际通用的GMP标准,设有预灌封注射器灌装线和西林瓶灌装线。基地的生产车间采用康希诺生物具有自主知识产权的腺病毒载体技术平台,平台具有快速制备病毒载体疫苗的能力,为应对新发、突发重大传染病疫情防控提供保障。2017年,平台曾成功开发我国唯一获批的重组埃博拉病毒病疫苗。

Comments (0)Add Comment

Write comment

security code
Write the displayed characters


busy
    Subscription    |     Advertising    |     Contact Us    |
Address: Magnetic Plaza, Building A4, 6th Floor, Binshui Xi Dao.
Nankai District. 300381 TIANJIN. PR CHINA
Tel: +86 22 23917700
E-mail: webmaster@businesstianjin.com
Copyright 2021 BusinessTianjin.com. All rights reserved.